NZ204385A

NZ204385A - Liquid pharmaceutical compositions containing salbutamol and one or more cellulose derivatives

Info

Publication number: NZ204385A
Application number: NZ204385A
Authority: NZ
Inventors: J M Padfield; C V Groom
Original assignee: Glaxo Group Ltd
Priority date: 1982-05-27
Filing date: 1983-05-27
Publication date: 1986-07-11
Also published as: PT76773B; AT390191B; IE831267L; ES522752A0; NL8301900A; IE55139B1; GR82681B; SE454946B; DE3319356A1; CH656308A5; FR2527442B1; NO163166C; ZW11883A1; CA1203176A; AU1503983A; IT8348384A0; DK167558B1; IL68805A0; PT76773A; ZA833854B

Description

New Zealand Paient Spedficaiion for Paient Number £04385 20438 Priority Date(s): P. 7.'. ?P., Complete Specification Filed: £ 7.. £ . H5 Class: /)£.y../?. £//&•'. 7/.Q® Publication Date: P.O. Journal, No: ,0 ?5 NO DRAWINGS NEW ZEALAND PATENTS ACT, J 953 No.: Date: COMPLETE SPECIFICATION v-j Po*\e«»tcr> PHARMACEUTICAL COMPOSITIONS K/We, GLAXO GROUP LIMITED A British Company of Clarges House 6-12 Clarges Street ^ London WlY 8DH, England hereby declare the invention for which i / we pray that a patent may be granted to iJ4ii/us, and the method by which it is to be performed, to be particularly described in and by the following statement:- _ 1 - (followed by page la) 2043 8 -la ~ Titloi PHARMACEUTICAL COMPOSITIQMg- The present invention relates to a pharmaceutical composition containing as active ingredient the 6-stimulant salbutamol.

Salbutamol [(a^-tert-butylaminomethyl)-4-hydroxy-1 3 m-xylene-a ,a -diol)] and its physiologically acceptable salts are described in British Patent Specification No. 1200886. In that specification there is reference to pharmaceutical compositions containing salbutamol and there is a description of solid and liquid 10 preparations for oral and intravenous use.

Liquid preparations of salbutamol and/or a physiologically acceptable salt thereof are conveniently water based and for oral use the preparations contain sucrose or sorbitol which acts both as a sweetener and 15 thickening agent.

Such pharmaceutical compositions have been successfully marketed. However, it is known that the presence of a substance such as sucrose, or sorbitol or glycerol in aqueous compositions of 20 salbutamol or a physiologically acceptable salt thereof is associated with an accelerated deterioration in the stability of the salbutamol in the composition.

We have now surprisingly found that the stability 204385 of salbutamol in aqueous formulations may be significantly enhanced by the presence of a cellulose derivative which forms a colloidal dispersion in water.

Thus, the present invention provides an improved pharmaceutical composition in liquid form which comprises dispersion of one or more cellulose derivatives in an aqueous solution of salbutamol and/or one or more of its physiologically acceptable salts• In the liquid preparation which is suitable for oral administration the cellulose derivative is a4vantageously used as thickening agent.

Suitable cellulose derivatives are those which form an optically transparent or opalescent dispersion in water, preferably an optically transparent colloidal dispersion.

Preferred cellulose derivatives include non-ionic derivatives such as alkyl and/or hydroxyalkyl ethers of cellulose, particularly C1-4 alkyl and/or hydroxy C^_4 alkylethers of cellulose for example, ethyl cellulose, methyl cellulose, ethyl methylcellulose hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropvl cellulose, hydroxyethyl methylcellulose, hydroxvpropyl methylcellulose and hydroxyethyl ethylcellulose . 2043 85 Suitable ionic cellulose derivatives include carboxymethylceullose and salts thereof such as the calcium or sodium salts.

Particularly preferred cellulose derivatives 5 are hydroxyethyl cellulose and more especially hydroxypropyl methylceullose.

A preferred salt of salbutamol for use in the pharmaceutical composition according to the invention is the sulphate.

The total amount of dispersible cellulose derivatives present in the pharmaceutical composition according to the invention is such that the resulting colloidal dispersion has the desired enhanced stability and has a viscosity suitable for its 15 proposed mode of administration. Preferably, the pharmaceutical composition contains at least 0.1% w/v of the cellulose derivatives.

For liquid preparations suitable for oral administration the total amount of cellulose 20 derivatives will be determined primarily by the requirement to obtain a solution with a viscosity suitable for oral administration, preferably within the range 5 to 10,000 centipoises, more preferably from 10 to 100 centipoises. 25 The concentration of the salbutamol or its salts in the formulation may be adjusted t.o suit the use 2043 8 for which the formulation is required and/or the patient's requirements. For example, for oral use the concentration is conveniently equivalent to lmg to 4mg, preferably 2mg, of salbutamol, expressed as salbutamol free base, per 5 ml of the liquid.

Preferably the pH of the pharmaceutical composition is in the range of from 2.5 to 7, more particularly 3.5 and this is conveniently achieved by the use of a buffer. For oral compositions, suitable buffers include a sodium citrate/citric acid buffer.

The pharmaceutical composition according to the invention may also contain an antimicrobial preservative, such as benzoic acid or a salt thereof which generates the acid in situ, or a methyl, ethyl, propyl or butyl hydroxybenzoate. For oral use the composition preferably also contains a flavouring, a sweetening agent such as saccharin sodium or sodium cyclamate and/or a colouring.

The pharmaceutical composition according to the invention may be prepared by dispersing one or more cellulose derivatives in water, and then adding or mixing with the salbutamol or physiologically acceptable salts thereof, conveniently dissolved in water, together with any optional components of the composition. <£-OC£ jh 204385 Illustrative examples of formulations (expressed as a 5 ml dose)for oral administration according to the invention are as follows:-Example 1 Salbutamol sulphate 2.40 mg Hydroxyethyl cellulose (Natrosol 250H) 22.5 mg Distilled water to 5 ml To prepare the formulation the hydroxyethyl cellulose is dispersed in water and then mixed with a solution of salbutamol sulphate in water.

Example 2 Salbutamol sulphate 2.40 mg Sodium citrate dihydrate 9.60 mg Citric acid monohydrate 15.15 mg Natrosol 250H 15.0 mg Distilled water to 5.0 ml To prepare the formulation the hydroxyethyl cellulose is dispersed in water, and then mixed with a solution of salbutamol and the buffers salts in water. 2043 Example 3 Salbutamol sulphate 2.40 mg Sodium citrate dihydrate 9.60 mg Citric acid monohydrate 15.25 mg Hydroxypropyl methylcellulose viscosity type 4000 22.5 mg Distilled water to 5 ml Example 4 Salbutamol sulphate B.P. 2.4 0 mg Sodium citrate B.P. 7.5 mg Citric acid monohydrate B.P. 25.0 mg Hydroxypropyl methylcellulose (viscosity type 4000) 22.5 mg Sodium benzoate B.P. 10.0 mg Saccharin sodium B.P. 2.5 mg Flavouring qS Purified water to 5 ml To prepare the formulations of Examples 3 and 4 20 the hydroxypropyl methylcellulose is dispersed in hot water, cooled and then mixed with an aqueous solution containing the salbutamol sulphate and the other components of the formulation. 1 2043S5

Claims

WHAT WE CLAIM IS:

1. A pharmaceutical composition in liquid form which comprises dispersion of one or more cellulose derivatives in an aqueous solution of salbutamol and/or one or more of its physiologically acceptable salts.

2. A pharmaceutical composition according to « claim 1, which comprises the one or more cellulose derivatives in a total amount of at least 0.1% w/v.

3. A pharmaceutical composition according to claim 1 or 2, wherein the cellulose derivative is an alkyl and/or hydroxyalkyl ether.

4. A pharmaceutical composition according to any of claims 1 or 2, in which the cellulose derivative is selected from ethyl cellulose, methyl cellulose, ethyl methylcellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulos carboxymethylcellulose' and salts of carboxymethylcellulos

5. A pharmaceutical composition according to claim 4, wherein the cellulose derivative is hydroxypropyl methylcellulose.

6. A pharmaceutical composition according to any of claims 1 to 5, which is formulated "for oral administration. \ -8 MAY 1986 204385

7. A pharmaceutical composition according to claim 6, which contains the one or more cellulose derivatives in a total amount such as to provide the liquid preparation - with a viscosity in the range of from 5 to 10,000 dentipoises.

8. A pharmaceutical composition according to claim 7, wherein the viscosity is in the range of from 10 to 100 centipoises.

9. A pharmaceutical composition according to any of claims 6 to 8, which contains salbutamol and/or one or more of its physiologically acceptable salts in a concentration of lmg to 4mg, expressed as salbutamol free base per 5 ml of liquid.

10. A pharmaceutical composition according to claim 9, wherein the concentration is 2mg expressed as salbutamol free base per 5 ml of liquid.

11. A pharmaceutical composition according to any of claims 1 to 10, having a pH of 3.5.

12. A pharmaceutical^composition substantially as herein described with reference to any of the specific Examples. DATED THIS 7 ^ DAY OF 19^ A. J. BAP. K & SON AGENTS FCR THE APPLICANTS ^-8 MAY 1986"